THX Pharma (Theranexus) announced on January 8 the online publication of its shareholder letter, according to a press release issued Wednesday evening.
The Lyon-based biopharmaceutical group, specializing in the treatment of rare neurological diseases, indicated that it has published its letter intended for shareholders. The document is available on the company's website, in the section dedicated to financial documents. The company also invites its shareholders to register to receive all its communications.
Current Pharmaceutical Developments
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
According to the press release, THX Pharma is currently developing two drugs. The first, TX01, is soon to be marketed in Europe by Exeltis, as well as in the United States, Canada, and Australia, for the treatment of Niemann-Pick disease type C and Gaucher's disease. The second, Batten-1, targets the juvenile form of Batten disease. The company also has a platform for antisense oligonucleotides developed in collaboration with research laboratories, still within the field of rare neurological diseases.
Market Presence and Information Integrity
THX Pharma, the commercial name of Theranexus, is listed on the Euronext Growth market in Paris under the mnemonic ALTHX. The press release specifies that the content distributed benefits from a system to combat the dissemination of false information certified by Finance Innovation. No financial figures or strategic direction was communicated in the announcement.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Context
Period
Period: 2025
Key reported figures
Revenue: 813K€
Net income: -3 002 k€
Guidance from the release
L'accord stratégique récemment conclu avec Biocodex,...
THX Pharma renforce sa solidité financière.
Risks mentioned
Pression sur les coûts de développement liée aux essais cliniques.
Incertitude réglementaire sur les projets de commercialisation.
Opportunities identified
Lancement clinique de TX01 et Batten-1 en 2026.
Accord stratégique avec Biocodex.
Visibilité financière sécurisée avec Biocodex.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
